Cephalon Inc., the mid-sized specialty pharma company has found a white knight. Just two weeks before a May 12 deadline required shareholders to tender their shares for or against a takeover offer by Valeant Pharmaceuticals International Inc., the company has accepted a $6.8 billion cash offer from Teva Pharmaceutical Industries Ltd.[See Deal][See Deal]
The deal will "transform Teva's branded business, as it will help us deliver on our strategic goal of creating a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?